{"product_id":"globalgreencross-soar-analysis","title":"Green Cross SOAR Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Green Cross SOAR Analysis provides a structured look at the company's strengths, opportunities, aspirations, and results for strategy, research, or planning. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration through ABO Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Green Cross Pharma strengthened upstream control by acquiring ABO Holdings, which operates 6 FDA-approved plasma collection centers in the United States. That move secures a steadier supply of high-quality U.S.-sourced plasma for ALYGLO and other blood products, helping reduce raw material cost swings. It also brings procurement in-house, which can improve margins by capturing more of the value chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafety Differentiation with CEX Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGC Pharma's ALYGLO uses proprietary CEX chromatography, a clear safety edge in the U.S. IVIG market. The process drives factor XIa below the limit of detection, which supports a lower thromboembolic-risk profile that the FDA closely watches for this class. In 2025, that 10% IVIG positioning helps ALYGLO stand out in a crowded market where safety and clot risk can decide prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Flu Vaccine Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGC Pharma's dominant flu vaccine position is a clear strength: it won South Korea's 2025-2026 seasonal flu vaccine bid for about 2.63 million doses, the largest award in the market. That scale gives the Company steady National Immunization Program demand and recurring cash flow.\u003c\/p\u003e\n\u003cp\u003eIt also moved fast to align production with the World Health Organization's trivalent guidance, including the removal of the B-Yamagata lineage. That operational flexibility helps protect share at home and supports funding for wider R\u0026amp;D. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Rare Disease Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGreen Cross's rare-disease portfolio, led by Hunterase for Hunter syndrome, is a strong export driver in Russia and other emerging markets. Hunterase sales reached about 74.4 billion KRW in 2025, up 20% year on year, showing solid demand in a market with high clinical barriers and long-term patient need.\u003c\/p\u003e\n\u003cp\u003eThis niche focus supports margins and helps Green Cross compete where few rivals can build scale. Even with geopolitical pressure, the franchise kept growing, which signals durable customer demand and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTurnaround in Operational Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGC Pharma's turnaround in operational efficiency shows in its break from eight straight years of fourth-quarter deficits in early 2026. Management cut losses at overseas units and raised Ochang plant utilization, while Barycela's 2025 sales doubled to 32.1 billion KRW, shifting the mix toward higher-margin products. That tighter cost base and stronger product focus point to a more durable profit path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Cross's 2025 Edge: More Plasma, Safer ALYGLO, Stronger Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross's strongest 2025 edge is upstream control: ABO Holdings added 6 FDA-approved U.S. plasma centers, tightening supply for ALYGLO and other blood products. ALYGLO's CEX process also drove factor XIa below detection, a real safety plus in IVIG. The Company's 2025-2026 flu bid win for about 2.63 million doses and Hunterase sales of 74.4 billion KRW show scale and durable niche demand.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 strength\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma supply\u003c\/td\u003e\n\u003ctd\u003e6 FDA centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALYGLO safety\u003c\/td\u003e\n\u003ctd\u003eFactor XIa below detection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlu vaccines\u003c\/td\u003e\n\u003ctd\u003e2.63 million doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHunterase sales\u003c\/td\u003e\n\u003ctd\u003e74.4 billion KRW\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear SOAR framework for analyzing Green Cross's strategic development potential\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Green Cross quickly turn strategic pain points into clear strengths, opportunities, aspirations, and results.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Market Scaling for ALYGLO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALYGLO's U.S. scale-up looks strong: by March 2026 it is on 75% of Pharmacy Benefit Manager formularies, which should widen access fast. Initial annual U.S. sales already topped $100 million, clearing the first major commercial hurdle. If the current pace holds, linear growth models point to about $300 million in annual revenue by 2028, helped by deeper sales into immunology centers and hospital networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMessenger RNA Platform Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, GC Pharma secured support for Phase 1 and 2 trials of its domestic COVID-19 mRNA vaccine candidate, creating a new platform pillar. The mRNA stack now can support targeted vaccines for infectious diseases and personalized immunotherapies, not just pandemic response. By internalizing candidate-to-production steps, Green Cross can act as a regional hub for future vaccine development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Pipeline Catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn early 2026, the tougher bar for mature biologics made GC Pharma's gene therapy pipeline more valuable. Its trial track record and ties with Artiva and GC Cell give it a practical path into CAR treatments, with 2 partnership routes aimed at hematologic cancers and solid tumors. That matters in a CGT market where clinical proof, not hype, drives faster regulatory and partnering gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoutheast Asian Geographic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSoutheast Asia's roughly 680 million people and rising immune-disorder diagnosis rates make it a large, still-underfilled market for plasma products. As immunoglobulin demand grows fastest in APAC in 2026, GC Pharma can extend beyond Korea and the U.S. with lower-cost supply for regional tenders.\u003c\/p\u003e\n\u003cp\u003eIts WHO-linked experience can support local regulators, speed access, and build trust with public buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Divestitures and Capital Reallocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGreen Cross's $38 million (50.5 billion KRW) divestment of its GC Wellbeing stake to the holding company gives it fresh capital to focus on core biopharma assets. That cash can help fund heavier U.S. marketing for ALYGLO and widen pediatric clinical trials, where execution can lift future sales more than consumer healthcare units. Reallocating capital this way cuts drag from non-core businesses and puts more resources behind higher-return growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Cross's Next Growth Surge: ALYGLO, APAC, and New Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross's best opportunities are ALYGLO's U.S. expansion, with 75% PBM coverage by March 2026 and first sales above $100 million, plus a wider APAC plasma market of about 680 million people. Its Phase 1\/2 mRNA vaccine program and CAR-T links with Artiva and GC Cell add new growth legs, while the $38 million GC Wellbeing sale frees capital for core biopharma.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGreen Cross Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the actual Green Cross SOAR analysis document you'll receive after purchase. This is not a sample or summary-the full version is unlocked once your order is complete. What you see here reflects the same professional, structured file included in your download. No surprises, just the real report ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003espirations\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Leadership in Specialized Immunoglobulin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGC Pharma is pushing ALYGLO as a safety-first IVIG brand, with FDA approval already in place for primary humoral immunodeficiency in adults. By 2027, it wants expanded pediatric labeling and published real-world evidence proving lower impurities, so it can shift from a Korea-led player to a North America benchmark. The end goal is a meaningful double-digit share of the private-insurance IVIG market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilding a Comprehensive Healthcare Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGC Pharma's \"Mission and Vision 2026\" points to a shift from drug maker to life sciences group spanning prevention, diagnosis, and treatment. The aim is a digital-led chain that links regional diagnosis centers with specialty therapy delivery, so patients get faster, more coordinated care. In chronic and rare disease care, this means moving from one-time sales to full life-cycle management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSovereign Health and Vaccine Independence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross is aiming for vaccine sovereignty by building a fully integrated domestic mRNA platform, aligned with the global 100-day vaccine mission backed by CEPI and other public health bodies. By the late 2020s, GC Pharma wants to move from pathogen detection to production in months, making it a key supplier for government health agencies. That role can attract priority state funding because it links supply security with national defense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZero-Impurity Manufacturing Standard\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGreen Cross aims to set a zero-impurity bar for biologics by refining cation exchange to cut heterophilic antibody interference and plasma allergens. In 2025, the pressure is real: infusion-related hospital readmissions can cost payers thousands per stay, and even small cuts in adverse events can move outcomes. That pitch is simple: cleaner products should mean safer infusions, fewer readmissions, and stronger proof of value for major payers and global health bodies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental and Supply Chain Stewardship\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGreen Cross Business management's 2030 goal to power major South Korean sites with 100% renewable energy fits a market where ESG is now a bid factor, not a side note. WHO and PAHO vaccine tenders increasingly favor suppliers with low-carbon, traceable logistics, and the global vaccine cold chain can lose up to 25% of doses without tight controls. If Green Cross cuts freight emissions and waste, it can win on ethics and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Cross Eyes U.S. IVIG Growth, 100-Day mRNA and 2030 Renewables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross's aspiration is to move from a Korea-led plasma and vaccine maker to a global rare-disease and public-health platform. It wants ALYGLO to reach a double-digit share of the U.S. private-insurance IVIG market, add pediatric labeling by 2027, and back that with real-world evidence. It also targets a fully integrated domestic mRNA platform for the 100-day vaccine mission and 100% renewable power at major South Korean sites by 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTheme\u003c\/th\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eALYGLO\u003c\/td\u003e\n\u003ctd\u003eDouble-digit U.S. share\u003c\/td\u003e\n\u003ctd\u003eScale in IVIG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emRNA\u003c\/td\u003e\n\u003ctd\u003e100-day response\u003c\/td\u003e\n\u003ctd\u003eVaccine readiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG\u003c\/td\u003e\n\u003ctd\u003e100% renewable by 2030\u003c\/td\u003e\n\u003ctd\u003eBid advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesults\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTotal Revenue Growth and Turnaround\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGC Pharma posted strong 2025 results, with consolidated sales of 1.37 billion dollars, or 1.99 trillion KRW, up 18.5% year on year. Operating profit climbed to 69.1 billion KRW, more than double the prior year, showing a clear turnaround. The move toward higher-margin export products is lifting both revenue and profitability, so the growth mix is improving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Adoption in the U.S. Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreen Cross saw rapid U.S. traction as ALYGLO reached about $27 million in first-quarter 2026 sales, or 37 billion KRW, more than 300% above its early launch run-rate. The patient base climbed from zero in mid-2024 to over 1,000 by early 2026, showing fast uptake in American immunology clinics. That pace suggests strong physician acceptance and a clearer path to scale in the U.S. market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Expansion of Global Exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross expanded global exports well in 2025, with WHO-ordered dose deliveries reinforcing its role in vaccine supply. Latin America and Southeast Asia now account for over 30% of total biopharma revenue, showing less dependence on South Korea. Barycela sales reached 32.1 billion KRW by 2026, a clear sign that export-led growth is scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin Recovery via Strategic Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEarly 2025 integration of ABO Holdings and ABO Plasma cut operating losses at weaker subsidiaries by 31%, according to 2026 reports. Higher utilization at the new plasma centers improved unit economics and helped hold raw material cost per liter steady. That cleaner internal profile removed prior one-time losses and left more room for reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong R\u0026amp;D and Regulatory Pipeline Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGC Pharma's selection for national mRNA platform projects is a clear R\u0026amp;D win and supports its research pipeline in 2025. The FDA center approvals for all six blood collection sites give the Company full regulatory coverage across its U.S. collection network. That removes major legal and logistics hurdles for expanding plasma supply. It also supports faster scale-up for U.S. commercial activity in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGC Pharma's Turnaround Gains Steam on Exports, U.S. Growth, and ALYGLO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGC Pharma's 2025 results showed a clear turnaround, with sales of 1.99 trillion KRW and operating profit of 69.1 billion KRW, up more than 2x year on year. Export-led products and higher U.S. traction lifted the mix, while ALYGLO reached about 37 billion KRW in Q1 2026 sales after a fast launch. New plasma and mRNA platform progress also strengthened the 2025 growth base.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SWOT Analysis Template","offers":[{"title":"Default Title","offer_id":57350727827838,"sku":"globalgreencross-soar-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/9204\/3902\/files\/globalgreencross-soar-analysis.webp?v=1777682142","url":"https:\/\/swot-analysis-template.com\/products\/globalgreencross-soar-analysis","provider":"SWOT Analysis Template","version":"1.0","type":"link"}